Health Canada eases restrictions on abortion pill Mifegymiso

0

Health Canada eases restrictions on abortion pill Mifegymiso

Sheryl Ubelacker, The Canadian Press
Published Tuesday, November 7, 2017 2:34PM EST

TORONTO -- Women who want to use the abortion pill Mifegymiso can now take it farther along in their pregnancy, Health Canada said Tuesday in announcing changes to how the medication is prescribed and dispensed.

The federal department said the abortion pill can now be prescribed up to nine weeks into a pregnancy, rather than the previous limit of seven weeks.

Continued: http://www.ctvnews.ca/health/health-canada-eases-restrictions-on-abortion-pill-mifegymiso-1.3667422

Read more

Canada: Doctor calls for stop of ‘demeaning’ practice of watching women swallow Mifegymiso ‘abortion pill’

0

Doctor calls for stop of 'demeaning' practice of watching women swallow Mifegymiso 'abortion pill'
Not required in Canada, but doctors at Regina General Hospital still do it

By Stephanie Taylor, CBC News
Posted: Aug 11, 2017

Doctors should stop the "demeaning" practice of supervising a woman while she swallows the Mifegymiso abortion pill, a professor says.

Dr. Wendy Norman teaches at the University of British Columbia and chairs family planning research for the Public Health Agency of Canada and Canadian Institutes of Health Research.

She said a myth exists that physicians are required to watch a patient ingest mifepristone — one of a two-drug combination packed together as Mifegymiso, for medical abortions.

Continued: http://www.cbc.ca/news/canada/saskatchewan/mifegymiso-regina-doctors-abortion-pill-supervision-1.4243642

Read more

Expert panel endorses public coverage for abortion pill in Canada

0

Expert panel endorses public coverage for abortion pill in Canada

Kelly Grant - HEALTH REPORTER
The Globe and Mail
Published Wednesday, Apr. 19, 2017

A long-awaited expert committee report on the abortion pill is recommending that provincial and territorial governments cover the $300 cost of the medication, The Globe and Mail has learned.

The Common Drug Review (CDR) endorsement is a crucial step toward taxpayer-funded reimbursement for drugs new to Canada, including Mifegymiso, a two-drug combination kit that pro-choice advocates hope will eventually make abortions easier to obtain outside big cities.

Continued at source: Globe & Mail: http://www.theglobeandmail.com/news/national/expert-panel-endorses-public-coverage-for-abortion-pill-in-canada/article34757082/

Read more

Abortion pill’s Canadian launch delayed by lack of coverage, distribution rules

0

Abortion pill's Canadian launch delayed by lack of coverage, distribution rules

Kelly Grant - HEALTH REPORTER
The Globe and Mail
Published Wednesday, Mar. 01, 2017

The Canadian launch of the abortion pill is proceeding more slowly than expected, with only five abortion clinics and a handful of big-city pharmacies across the country ordering the medication since its debut in January.

Abortion providers say confusion over distribution rules and a lack of public drug coverage are partly behind the sluggish introduction of Mifegymiso, a $300 pill combination that supporters hope will eventually make it easier for rural and small-town women to end their unwanted pregnancies.

“It’s been terribly slow,” Ellen Wiebe, the medical director of the Willow Women’s Clinic in Vancouver, said of the abortion pill’s roll-out. “We’re the big customer. That shouldn’t be. It should be all over the country.”

Continued at source: Globe & Mail: http://www.theglobeandmail.com/news/national/abortion-pills-canadian-launch-delayed-by-lack-of-coverage-distribution-rules/article34181063/

Read more

Long-awaited abortion pill Mifegymiso makes Canadian debut

0

Long-awaited abortion pill Mifegymiso makes Canadian debut
Kelly Grant - HEALTH REPORTER

The Globe and Mail

Published Friday, Jan. 20, 2017

The abortion pill is finally available in Canada.

The first shipments of Mifegymiso arrived earlier this week at two women’s health clinics in Vancouver and Calgary, marking the beginning of a potential sea change in how women in Canada choose to end their pregnancies.

“We were over the moon,” said Celia Posyniak, the executive director of Calgary’s Kensington Clinic, the first place in the country to provide the medication to a patient. “There’s a few of us who’ve been here for 25 years or more and we’ve been waiting for it for all that time. Canada was definitely a laggard.”

[continued at link]
Source, Globe & Mail: http://www.theglobeandmail.com/news/national/long-awaited-abortion-pill-mifegymiso-rolls-out-in-canada/article33695167/

Read more

Canadian debut of abortion pill Mifegymiso delayed to January

0

by Cassandra Szklarski

TORONTO — The Canadian Press
Published Monday, Nov. 28, 2016 3:08PM EST

The much-anticipated arrival of the abortion pill Mifegymiso in Canada has been delayed until the new year.

The drug’s Canadian distributor, Celopharma Inc., says it now expects to launch “some time in January.”

Company president Paula Tenenbaum gave few details in a terse email exchange but said it was related to “a change in manufacturing site.”

Last month, Tenenbaum said Mifegymiso was on track for a November debut in Canada.

[continued at link]
Source: Globe & Mail, Canadian Press

Read more

The $300 Abortion Drug Coming to Canada Probably Won’t Be Covered By Health Insurance

0

By Manisha Krishnan
Senior Writer, VICE

September 26, 2016

Pro-choice advocates say the high cost of an abortion drug that likely won't be covered by provincial health care plans will limit abortion access to Canadian women who don't live in major urban centres.

Mifegymiso, hailed as the gold-standard in abortion medication, is a set of two pills that allows women to terminate their pregnancies. It will become available in Canada this year—it's been in the US since 2000—and can be taken within the first 49 days of a pregnancy. But according to a report by the Globe and Mail, the company bringing the drug here, Celopharma, has opted out of an application process that is required for the drug to be covered by the provinces. Known as the Common Drug Review, the application would cost Celopharma $72,000. Not completing the process means Mifegymiso will only be covered by employment and private insurance, or will cost patients $300 out of pocket.

Joyce Arthur, executive director of the Abortion Rights Coalition of Canada, told VICE the decision is "very disappointing."

[continued at link]
Source: VICE.com

Read more